SEC Form 4 · accession 0001179110-17-002062
MOMENTA PHARMACEUTICALS INC · MNTA
Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗
Reporting owner
Matthew P. Ottmer
Officer — Chief Operating Officer
Period of report
Feb 7, 2017
Accepted (ET)
Feb 9, 2017 · 4:52 pm EST
Rule 10b5-1 plan
unknown — predates the checkbox
Issuer CIK
0001235010
Table I — non-derivative securities
No Table I lines on this filing.
Table II — derivative securities
| Security | Conv. / exercise price | Date | Code | Shares | A/D | Exercisable | Expires | Underlying | Underlying shares | Owned after | D/I |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Stock Option (Right to Buy)F1 | $18.85 | Feb 7, 2017 | A | 48,000 | A | — | Feb 7, 2027 | Common Stock | 48,000 | 48,000 | D |
| Restricted Stock UnitsF2,F3 | — | Feb 7, 2017 | A | 24,000 | A | — | — | Common Stock | 24,000 | 24,000 | D |
Explanation of responses
- F1Subject to certain criteria, the stock option will vest and become exercisable with respect to 25% of the shares on the first anniversary of the grant date, and the remainder will vest in equal quarterly installments over the subsequent three years.
- F2Each restricted stock unit represents a contingent right to receive one share of MNTA common stock.
- F3Subject to certain criteria, the restricted stock units will vest with respect to 25% of the shares on the first anniversary of the grant date, and the remainder will vest in equal quarterly installments over the subsequent three years.